Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Catharina Ziekenhuis Eindhoven
Changhai Hospital
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Region Skane
Hôpital Edouard Herriot
Emory University
University of Miami
Mayo Clinic
Nantes University Hospital
Odense University Hospital
Odense University Hospital
Fudan University
City of Hope Medical Center
Zhongshan People's Hospital, Guangdong, China
French Society of Digestive Endoscopy
National Institutes of Health Clinical Center (CC)
Case Western Reserve University
Memorial Sloan Kettering Cancer Center
Servicio de Salud Metropolitano Sur Oriente
Sun Yat-sen University
City of Hope Medical Center
Eye & ENT Hospital of Fudan University
Oslo University Hospital